Actively Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Led by Xiaojun Chen · Updated on 2025-08-11
29
Participants Needed
2
Research Sites
245 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
CONDITIONS
Official Title
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis by hysteroscopy of well-differentiated early-stage endometrioid endometrial cancer without muscle invasion
- Body mass index (BMI) of 30 kg/m2 or higher
- No signs of spread outside the uterus on MRI, CT, or ultrasound
- Prior treatment with progestin, including megestrol acetate (≥160 mg daily), medroxyprogesterone acetate (≥250 mg daily), or use of levonorgestrel intrauterine system (LNG-IUS)
- Progestin-insensitive defined as stable disease after 7 months or no complete response after 10 months of progestin use
- Desire to preserve fertility or uterus
- Able to comply with treatment and follow-up
You will not qualify if you...
- Severe medical conditions or significantly impaired liver or kidney function
- Confirmed endometrial cancer with muscle invasion or spread beyond the uterus
- Other types of endometrial cancer or reproductive system cancers
- Breast cancer or other hormone-dependent diseases preventing use of GnRHa or letrozole
- Strong preference for hysterectomy or other conservative treatments
- Known or suspected pregnancy
- Acute serious diseases such as stroke, heart attack, or history of thrombosis
- Smoking more than 15 cigarettes per day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China
Actively Recruiting
2
Obstetrics and Gynecology Hospital, Fudan University
Shanghai, China
Actively Recruiting
Research Team
X
Xiaojun Chen, PhD
CONTACT
P
Pengfei Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here